• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What's new in intensive care: disease tolerance.

作者信息

Powell Rachel E, Soares Miguel P, Weis Sebastian

机构信息

Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, Pittsburgh, PA, USA.

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Intensive Care Med. 2023 Oct;49(10):1235-1237. doi: 10.1007/s00134-023-07130-8. Epub 2023 Jun 23.

DOI:10.1007/s00134-023-07130-8
PMID:37353606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10556172/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f320/10556172/351b606b2909/134_2023_7130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f320/10556172/351b606b2909/134_2023_7130_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f320/10556172/351b606b2909/134_2023_7130_Fig1_HTML.jpg

相似文献

1
What's new in intensive care: disease tolerance.重症监护领域的新进展：疾病耐受性。
Intensive Care Med. 2023 Oct;49(10):1235-1237. doi: 10.1007/s00134-023-07130-8. Epub 2023 Jun 23.
2
Update on health care in Canada: what's right, what's wrong, what's left.加拿大医疗保健最新情况：哪些方面做得对，哪些方面存在问题，以及未来走向。
J Public Health Policy. 1998;19(3):267-88.
3
Small animal dermatopathology: 'what's old, what's new, what's borrowed, what's useful'.小动物皮肤病理学：“旧闻、新闻、借鉴、实用”。
Semin Vet Med Surg Small Anim. 1987 Aug;2(3):162-5.
4
A commentary on the evolution of NIH: what's in, what's out, what's hot, what's not.关于美国国立卫生研究院发展历程的述评：哪些入选，哪些落选，哪些热门，哪些冷门。
Integr Physiol Behav Sci. 1998 Apr-Jun;33(2):115-7. doi: 10.1007/BF02688652.
5
Cardiovascular product update and evaluation. What's hot, what's not, what's in, what's out.心血管产品更新与评估。热门产品、冷门产品、流行产品、淘汰产品。
J Interv Cardiol. 1994 Apr;7(2):203-4. doi: 10.1111/j.1540-8183.1994.tb00905.x.
6
Cardiovascular product update and evaluation. What's hot, what's not, what's in, what's out.心血管产品更新与评估。热门产品、冷门产品、流行产品、淘汰产品。
J Interv Cardiol. 1992 Mar;5(1):67-8. doi: 10.1111/j.1540-8183.1992.tb00827.x.
7
The Editor's Workshop: Pediatric and adolescent gynecology: What's the issue? What's the answer? What's the big picture? What's the national perspective?编辑工作室：儿科与青少年妇科：问题是什么？答案是什么？全局情况如何？全国视角怎样？
J Pediatr Adolesc Gynecol. 2009 Aug;22(4):195-6. doi: 10.1016/j.jpag.2009.06.001.
8
Cardiovascular disease in women: what's different? What's new? What's unresolved?女性心血管疾病：有何不同？有何新进展？有哪些尚未解决的问题？
Ann N Y Acad Sci. 1994 Dec 30;736:147-57. doi: 10.1111/j.1749-6632.1994.tb12827.x.
9
Dermatologic therapy--1960. What's new? and what's true of what's new?皮肤病治疗——1960年。有哪些新进展？新进展中哪些是真实可靠的？
Acta Derm Venereol. 1961;41:187-93.
10
What's new and what's true of what's new in dermatology.皮肤病学领域的新进展以及这些新进展的真实性。
Calif Med. 1955 Jul;83(1):1-5.

引用本文的文献

1
Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.表柔比星治疗脓毒症和脓毒性休克（EPOS-1）：一项随机、安慰剂对照的IIa期剂量递增试验的研究方案
BMJ Open. 2024 Apr 22;14(4):e075158. doi: 10.1136/bmjopen-2023-075158.
2
Targeting the host response in sepsis: current approaches and future evidence.靶向脓毒症的宿主反应：当前方法和未来证据。
Crit Care. 2023 Dec 6;27(1):478. doi: 10.1186/s13054-023-04762-6.

本文引用的文献

1
Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis.糖皮质激素抵抗合并高乳酸血症导致脓毒症致死性休克。
Cell Metab. 2021 Sep 7;33(9):1763-1776.e5. doi: 10.1016/j.cmet.2021.07.002. Epub 2021 Jul 23.
2
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.TOP1 抑制疗法可预防 SARS-CoV-2 引起的致命性炎症。
Cell. 2021 May 13;184(10):2618-2632.e17. doi: 10.1016/j.cell.2021.03.051. Epub 2021 Mar 30.
3
Disease Tolerance as an Inherent Component of Immunity.疾病耐受作为免疫的固有组成部分。
Annu Rev Immunol. 2019 Apr 26;37:405-437. doi: 10.1146/annurev-immunol-042718-041739. Epub 2019 Jan 23.
4
Metabolic Adaptation Establishes Disease Tolerance to Sepsis.代谢适应建立对脓毒症的疾病耐受性。
Cell. 2017 Jun 15;169(7):1263-1275.e14. doi: 10.1016/j.cell.2017.05.031.
5
Tracking Resilience to Infections by Mapping Disease Space.通过绘制疾病空间来追踪对感染的抵抗力
PLoS Biol. 2016 Apr 18;14(4):e1002436. doi: 10.1371/journal.pbio.1002436. eCollection 2016 Apr.
6
Homeostasis, inflammation, and disease susceptibility.体内平衡、炎症与疾病易感性。
Cell. 2015 Feb 26;160(5):816-827. doi: 10.1016/j.cell.2015.02.010.
7
Tissue damage control in disease tolerance.疾病耐受中的组织损伤控制。
Trends Immunol. 2014 Oct;35(10):483-94. doi: 10.1016/j.it.2014.08.001. Epub 2014 Aug 30.
8
Anthracyclines induce DNA damage response-mediated protection against severe sepsis.蒽环类抗生素诱导 DNA 损伤反应介导的严重脓毒症保护作用。
Immunity. 2013 Nov 14;39(5):874-84. doi: 10.1016/j.immuni.2013.08.039. Epub 2013 Oct 31.
9
Severe sepsis and septic shock.严重脓毒症和脓毒性休克。
N Engl J Med. 2013 Aug 29;369(9):840-51. doi: 10.1056/NEJMra1208623.
10
Disease tolerance as a defense strategy.疾病耐受力作为一种防御策略。
Science. 2012 Feb 24;335(6071):936-41. doi: 10.1126/science.1214935.